DARA BioSciences to Present at the 13th Annual Biotech & Specialty Pharmaceuticals Industry Investor Conference of the New York Society of Security Analysts ("NYSSA").

RALEIGH, N.C. -- DARA BioSciences, Inc. (NASDAQ: DARA), a development-stage biopharmaceutical company, today announced that the Company will present at the New York Society of Security Analysts' 13th Annual Biotech & Specialty Pharmaceuticals Industry investor conference to be held on December 1 in New York City. The New York Society of Security Analysts (NYSSA) serves 11,000 members and 30,000 Wall Street decision makers.

"It is an honour for DARA to be invited to speak," commented Richard Franco, DARA's President, CEO and Chairman. "DARA has two drug candidates in the clinic and this is a great opportunity to update the investment community on their progress."

DARA is scheduled to present at 1:30pm EST on December 1. Interested parties can access a live web cast of the presentation through the Company's website at www.darabio.com. A replay of the presentation will be available at the same location.

About DARA BioSciences, Inc.

DARA BioSciences, Inc. is a Raleigh, North Carolina based development-stage biopharmaceutical company that acquires promising therapeutic small molecules and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. Presently DARA has two drug candidates with cleared IND's (Investigational New Drug) Applications from the US FDA. One of these drug candidates KRN5500 has successfully completed a Phase 2a clinical trial treating cancer patients for neuropathic pain. DARA has a portfolio of drug candidates for neuropathic pain, type 2 diabetes, and psoriasis. For more information please contact the Company at 919-872-5578 or visit our web site at http://www.darabio.com.